CONMED Co. (CNMD) Declares Quarterly Dividend of $0.20
CONMED (NASDAQ:CNMD) announced a quarterly dividend on Monday, August 25th, Analyst Ratings Network reports. Stockholders of record on Monday, September 15th will be paid a dividend of 0.20 per share on Monday, October 6th. This represents a $0.80 annualized dividend and a dividend yield of 2.13%.
On a related note, analysts at Zacks reiterated a “neutral” rating on shares of CONMED in a research note on Friday, July 18th. They now have a $44.00 price target on the stock.
CONMED (NASDAQ:CNMD) opened at 37.62 on Monday. CONMED has a 52 week low of $30.86 and a 52 week high of $50.47. The stock has a 50-day moving average of $39.83 and a 200-day moving average of $43.99. The company has a market cap of $1.029 billion and a price-to-earnings ratio of 30.10.
CONMED (NASDAQ:CNMD) last posted its quarterly earnings results on Wednesday, July 23rd. The company reported $0.47 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.47. The company had revenue of $188.20 million for the quarter, compared to the consensus estimate of $190.62 million. During the same quarter in the prior year, the company posted $0.43 earnings per share. The company’s quarterly revenue was down 2.5% on a year-over-year basis. Analysts expect that CONMED will post $1.87 EPS for the current fiscal year.
In other CONMED news, EVP William Abraham sold 15,986 shares of the stock in a transaction that occurred on Thursday, August 21st. The stock was sold at an average price of $37.71, for a total transaction of $602,832.06. The transaction was disclosed in a legal filing with the SEC, which is available at this link.
CONMED Corporation (NASDAQ:CNMD) is a medical technology company/ The Company emphasizes on surgical devices and equipment for minimally invasive procedures and monitoring.
Receive News & Ratings for CONMED Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CONMED Co and related companies with Analyst Ratings Network's FREE daily email newsletter.